Objective To explore the feasibility of sirolimus as an alternative graft versus host disease (GVHD)prophylaxis in patients with kidney injury after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Metho...
from the clinical trial of CAR-T technique in the Treatment of Malignant Hematological Tumors registered on ClinicalTrials.gov(NCT05618041).
1.INTRODUCTION。CD7 is an ideal chimeric antigen receptor(CAR)target for T-cell acute lymphocytic leukemia(T-ALL).Donor-derived CAR-T-cell therapy,as an emerging treatment strategy,shows excellent efficacy in refracto...
Allogeneic hematopoietic cell transplantation(Allo-HCT)is a curative therapy for hematologic malignancies owing to graft-versus-leukemia/lymphoma(GVL)activity mediated by alloreactive donor T cells,but graft-versus-ho...
Graft versus host disease(GvHD)is the clinical condition in which bone marrow-derived mesenchymal stromal cells(MsCs)have been most frequently studied.In this review,we summarize the experience from clinical trials th...
This work is supported in part by SmartState Cancer Stem Cell Biology&Therapy Program and by R01 grants from the National Institutes of Health,including AI118305,HL140953 and CA258440(X.-Z.Y.).
Graft-versus-host disease (GVHD) significantly contributes to patient morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HSCT). Sphingosine-1-phosphate (S1P) signaling is involved in the...